Zusammenfassung
Autoantikörper sind bei der systemischen Sklerose (SSc) und ihren Varianten die bislang bestbekannte immunologische Veränderung. Mehr als 95% der Patienten mit SSc haben antinukleäre oder andere Autoantikörper im Serum. Bei etwa 90% der Patienten mit antinukleären Antikörpern (ANA) finden sich Sklerodermie-assoziierte Autoantikörper, die eine hohe Spezifität für die SSc aufweisen. Diese Antikörper schließen einander gegenseitig weitgehend aus und sind früh und persistierend im Krankheitsverlauf nachweisbar. Durch die Sklerodermie-assoziierten Autoantikörper charakterisierte SSc-Patienten bilden klinisch, genetisch und prognostisch relativ homogene Subgruppen der Erkrankung. Über diese diagnostisch relevanten Autoantikörper hinaus wurden zahlreiche weitere Autoantikörper bei der SSc beschrieben, die jedoch weder SSc-spezifisch noch einander ausschließend vorkommen und deren Antigene erst teilweise charakterisiert sind. Für einige dieser Autoantikörper wird aber verstärkt die noch nicht beantwortete Frage nach einer direkten Beteiligung an der Pathogenese der Erkrankung diskutiert.
Abstract
In systemic sclerosis (SSc) and its variants, autoantibodies are the best known immunological aberration. In more than 95% of the patients, antinuclear antibodies or other autoantibodies can be detected. In about 90% of SSc patients with antinuclear antibodies, scleroderma associated autoantibodies highly specific for systemic sclerosis are found. These autoantibodies usually exclude each other in individual patients, and they are detectable early, persisting during the course of the disease. SSc patients characterized by scleroderma associated autoantibodies belong to disease subsets which are relatively homogeneous in clinical, genetic and prognostic terms. Besides these diagnostically relevant autoantibodies, numerous additional ones have also been described. These are neither SSc specific nor mutually exclusive, and their antigens have only been partially characterized. Some, however, are thought to be relevant to the as yet unanswered question of whether autoantibodies are directly involved in SSc pathogenesis.
Literatur
Akimoto S, Ishikawa O, Takagi H, Miyachi Y (1998) Immunological features of patients with primary biliary cirrhosis (PBC) overlapping systemic sclerosis: a comparison with patients with PBC alone. J Gastroenterol Hepatol 13: 897–901
Arbuckle MR, McClain MT, Rubertone MV et al. (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349: 1526–1533
Brinckmann J, Hunzelmann N, El Hallous E et al. (2005) Absence of autoantibodies against correctly folded recombinant fibrillin-1 protein in systemic sclerosis patients. Arthritis Res Ther 7: R1221–R1226
Cepeda EJ, Reveille JD (2004) Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol 16: 723–732
Chizzolini C, Raschi E, Rezzonico R et al. (2002) Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 46: 1602–1613
Chung L, Utz PJ (2004) Antibodies in scleroderma: direct pathogenicity and phenotypic associations. Curr Rheumatol Rep 6: 156–163
Conrad K, Mehlhorn J (2000) Diagnostic and prognostic relevance of autoantibodies in uranium miners. Int Arch Allergy Immunol 123: 77–91
Crilly A, Hamilton J, Clark CJ et al. (2002) Analysis of transforming growth factor beta 1 gene polymorphisms in patients with systemic sclerosis. Ann Rheum Dis 61: 678–681
Dick T, Mierau R, Bartz-Bazzanella P et al. (2002) Coexistence of anti-topoisomerase 1 and anti-centromere antibodies in patients with systemic sclerosis. Ann Rheum Dis 61: 121–127
Dodig TD, Mack KT, Cassarino DF, Clark SH (2001) Development of the tight-skin phenotype in immune-deficient mice. Arthritis Rheum 44: 723–727
Eaker EY, Kuldau JG, Verne GN et al. (1999) Myenteric neuronal antibodies in scleroderma: passive transfer evokes alterations in intestinal myoelectric activity in a rat model. J Lab Clin Med 133: 551–556
Fregeau DR, Leung PS, Coppel RL et al. (1988) Autoantibodies to mitochondria in systemic sclerosis. Frequency and characterization using recombinant cloned autoantigen. Arthritis Rheum 31: 386–392
Fujimoto M, Sato S (2005) B lymphocytes and systemic sclerosis. Curr Opin Rheumatol 17: 746–751
Goldblatt F, Gordon TP, Waterman SA (2002) Antibody-mediated gastrointestinal dysmotility in scleroderma. Gastroenterology 123: 1144–1150
Greidinger EL, Zang Y, Jaimes K et al. (2006) A murine model of mixed connective tissue disease induced with U1 small nuclear RNP autoantigen. Arthritis Rheum 54: 661–669
Hénault J, Robitaille G, Senécal JL, Raymond Y (2006) DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 54: 963–973
Hill MB, Phipps JL, Cartwright RJ et al. (1996) Antibodies to membranes of endothelial cells and fibroblasts in scleroderma. Clin Exp Immunol 106: 491–497
Howe S, Eaker EY, Sallustio JE et al. (1994) Antimyenteric neuronal antibodies in scleroderma. J Clin Invest 94: 761–770
Hu PQ, Fertig N, Medsger TA Jr, Wright TM (2003) Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 48: 1363–1373
Johnson RW, Tew MB, Arnett FC (2002) The genetics of systemic sclerosis. Curr Rheumatol Rep 4: 99–107
Kallenberg CGM, Wouda AA, Hoet MH, van Venrooij WJ (1988) Development of connective tissue disease in patients presenting with Raynaud’s phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 47: 634–641
Kaufman LD, Gruber BL, Marchese MJ, Seibold JR (1989) Anti-IgE autoantibodies in systemic sclerosis (scleroderma). Ann Rheum Dis 48: 201–205
Kuwana M, Kaburaki J, Mimori T et al. (2000) Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 43: 1074–1084
Lee EB, Kim JY, Lee YJ et al. (2004) Transforming growth factor-beta1 polymorphisms in Korean patients with systemic sclerosis. Tissue Antigen 63: 491–495
LeRoy EC, Medsger TA (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28: 1573–1576
Lunardi C, Bason C, Navone R et al. (2000) Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nature Med 6: 1183–1186
Maricq HR, Valter I (2004) A working classification of scleroderma spectrum disorders: a proposal and the results of testing on a sample of patients. Clin Exp Rheumatol 22: S5–S13
Masi AT, Rodnan GP, Medsger TA et al. (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23: 581–590
Mierau R, Genth E (2002) Neue Aspekte der Autoantikörper-Diagnostik bei Kollagenosen. Z Rheumatol 61: 355–366
Momot T, Koch S, Hunzelmann N et al. (2004) Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum 50: 1561–1565
Nadashkevich O, Davis P, Fritzler MJ (2004) A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit 10: CR615–CR621
Nielen MMJ, van Schaardenburg D, Reesink HW et al. (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis – A study of serial measurements in blood donors. Arthritis Rheum 50: 380–386
Nishijima C, Hayakawa I, Matsushita T et al. (2004) Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 138: 357–363
Ohtsuka T, Yamakage A, Yamazaki S (2002) The polymorphism of transforming growth factor-beta1 gene in Japanese patients with systemic sclerosis. Br J Dermatol 147: 458–463
Rantapää Dahlqvist S, deJong BAW, Berglin E et al. (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48: 2741–2749
Reveille JD, Fischbach M, McNearney T et al. (2001) Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 30: 332–346
Sato S, Hamaguchi Y, Hasegawa M, Takehara K (2001) Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology (Oxford) 40: 1135–1140
Sato S, Hayakawa I, Hasegawa M et al. (2003) Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 120: 542–547
Sato H, Lagan AL, Alexopoulou C et al. (2004) The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. Arthritis Rheum 50: 558–564
Senécal JL, Hénault J, Raymond Y (2005) The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma). J Rheumatol 32: 1643–1649
Sgonc R, Gruschwitz MS, Boeck G et al. (2000) Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 43: 2550–2562
Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35: 35–42
Sugiura Y, Banno S, Matsumoto Y et al. (2003) Transforming growth factor beta1 gene polymorphism in patients with systemic sclerosis. J Rheumatol 30: 1520–1523
Tan FK, Arnett FC, Antohi S et al. (1999) Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J Immunol 163: 1066–1072
Tan FK, Arnett FC, Reveille JD et al. (2000) Autoantibodies to fibrillin 1 in systemic sclerosis – Ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. Arthritis Rheum 43: 2464–2471
Tsuchiya N, Kuroki K, Fujimoto M et al. (2004) Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. Arthritis Rheum 50: 4002–4007
Weiner ES, Hildebrandt S, Senécal JL et al. (1991) Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud’s disease. Arthritis Rheum 34: 68–77
Zhou X, Tan FK, Milewicz DM et al. (2005) Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the „scleroderma phenotype“. J Immunol 175: 4555–4560
Interessenkonflikt
Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mierau, R., Genth, E. Sklerodermie-assoziierte Autoantikörper – klinische und diagnostische Relevanz. Z. Rheumatol. 65, 279–284 (2006). https://doi.org/10.1007/s00393-006-0067-y
Issue Date:
DOI: https://doi.org/10.1007/s00393-006-0067-y